Antibody Persistence and Booster Vaccination During the Second and Fifth Years of Life in a Cohort of Children Who Were Born Prematurely

Omeñaca, F; García-Sicilia, José; Boceta, Reyes; Sistiaga-Hernando, Alessandra; Garcı́a-Corbeira, Pilar

doi:10.1097/inf.0b013e318124a9c8

Cited by 35 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 This risk may be due to several factors, including reduced materno-fetal transfer of pneumococcal antibodies 3 and a decreased response to Streptococcus pneumoniae due to an immature immune system. 4 Studies evaluating immune responses of preterm infants receiving pneumococcal vaccinations are scarce, and methodologic differences limit interpretation of the findings. 2,[5][6][7] However, the data suggest that gestational age (GA) and vaccination timing (eg, allowing for immune maturation) may affect the ability of preterm infants to respond adequately to immunization.…”

Section: What This Study Addsmentioning

confidence: 99%

13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants

et al. 2015

View full text Add to dashboard Cite

OBJECTIVES: This study evaluated the immune response and safety profile of 13-valent pneumococcal conjugate vaccine (PCV13) in preterm infants compared with term infants.METHODS: This Phase IV, open-label, 2-arm, multicenter, parallel-group study enrolled 200 healthy infants (preterm, n = 100; term, n = 100) aged 42 to 98 days. All subjects received PCV13 at ages 2, 3, 4 (infant series), and 12 (toddler dose [TD]) months, together with routine vaccines (diphtheriatetanus-acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine and meningococcal group C conjugate vaccine).RESULTS: Most subjects achieved an anticapsular immunoglobulin G (IgG) antibody concentration $0.35 mg/mL for all serotypes: .85% after the infant series (except preterm infants for serotypes 5, 6A, and 6B) and .97% after TD (except for serotype 3). Preterm infants had overall lower IgG geometric mean concentrations compared with term infants; however, geometric mean fold increases after TD were similar for all serotypes. Opsonophagocytic activity results were consistent with IgG results and titers increased after TD in both groups for all serotypes, including serotype 3. PCV13 was generally well tolerated, with similar safety profiles in all preterm subgroups.CONCLUSIONS: Immune responses were lower in preterm infants than in term infants. However, the majority of subjects in both groups achieved both pneumococcal serotype-specific IgG antibody levels after the infant series that exceeded the World Health Organization-established threshold of protection and functional antibody responses. Responses were uniformly higher after TD, reinforcing the importance of a timely booster dose. PCV13 was well tolerated regardless of gestational age.

show abstract

Section: What This Study Addsmentioning

confidence: 99%

13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants

et al. 2015

View full text Add to dashboard Cite

show abstract

“…2 Few studies have evaluated long term antibody persistence following primary and booster vaccination with DTPa-HBV-IPV/Hib to date. 3,4 Serological follow-up of German children 3-4 years after 3-dose primary vaccination and a booster dose at 12-18 months of age showed persisting antibody concentrations associated with seroprotection in more than 90% of vaccinees against diphtheria, hepatitis B, Hib and the three poliovirus types, and 76.4% against tetanus. 3 We report two serological follow up studies conducted in Germany in healthy children between 4 and 9 years of age who had been previously primed and boosted with four doses of combined DTPa-HBV-IPV/Hib vaccine in previous GSK-sponsored clinical trials.…”

mentioning

confidence: 99%

Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib

Zinke¹,

Disselhoff²,

Gartner³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

Combination vaccines induce immunity against multiple diseases in a single injection and thus facilitate delivery of complex vaccination schedules. Use of combination vaccines increases both vaccine coverage and the timeliness of vaccination.1 Infanrix hexa TM , the combined hexavalent diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine [DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals (GSK), Rixensart, Belgium] is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. DTPa-HBV-IPV/Hib contains ≥30 IU diphtheria toxoid, ≥40 IU tetanus toxoid, 25 μg pertussis toxin (PT), 25 μg filamentous haemagglutinin (FHA), 8 μg pertactin (PRN), 10 μg recombinant HBsAg, 40D, 8D and 32D antigen units of poliovirus types 1, 2 and 3 respectively and 10 μg Hib polyribosylribitol-phosphate (PRP) conjugated to tetanus toxoid.Background: the combined diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae conjugate vaccine (Dtpa-HBV-IpV/Hib, Infanrix Hexa tM GlaxoSmithKline Biologicals, rixensart, Belgium) is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. the persistence of the immune response in children aged 4-6 and 7-9 years of age previously vaccinated with four doses of Dtpa-HBV-IpV/Hib vaccine was assessed (www.clinical trials.gov.au 106744 NCt00356564 and 106745 NCt00335881).Methods: A blood sample was collected from 403 children, all of whom had received 3-dose primary vaccination and a booster dose in the second year of life with Dtpa-HBV-IpV/Hib, in previous clinical vaccine trials in Germany.results: Mean time from the fourth Dtpa-HBV-IpV/Hib dose until serological follow-up ranged between 3.6 and 6.4 years. After the 4 th Dtpa-HBV-IpV/Hib dose, in subjects who had not received additional booster doses, seroprotective antibody levels persisted up to 9 years of age in ≥90% of subjects for diphtheria, Hib and poliomyelitis, in 77.2% subjects for Hepatitis B and in 64.7% of subjects for tetanus. Anti-pertussis toxin antibodies remained detectable in no more than 38.2% of subjects.Conclusion: With the exception of pt, the combined Dtpa-HBV-IpV/Hib induces long lasting immune response against all vaccine antigens. Falling seropositivity against pt over time supports the recommended administration of a pertussis booster dose in 5-6 year old children in Germany.

show abstract

“…Safety and tolerability were identical in both groups. These data indicated applicability of the immunization scheme 2+1 for premature infants [41]. PCV7 (scheme -2-4-6 months) in the smallest premature children (birth weight <1,000g) creates a protective antibody level (>0.35mcg/ml) more rarely than in children of 1,000-1,500g of weight only in connection with serotypes 6B (85 to 96%) and 23F (88 to 97%).…”

Section: Vaccine Against the Infection Caused By Haemophilus Influenzmentioning

confidence: 87%